CMPO, US20464C1080

Compose Cure stock holds at USD 2.84 as losses narrow

Published on 09/22/2026 at 08:35 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Compose Cure stock traded at USD 2.84 on September 22, 2026, with a market value of USD 318.6 million. Second-quarter revenue reached USD 3.2 million.

CMPO, US20464C1080, Illustration mit AI erstellt.

Compose Cure, Inc. (US20464C1080) traded at USD 2.84 on Nasdaq on September 22, 2026, while its market capitalization stood at USD 318.6 million. The latest reported quarter showed revenue of USD 3.2 million and a net loss of USD 0.18 per share.

Revenue remains the key measure

Compose Cure reported second-quarter 2026 revenue of USD 3.2 million, compared with USD 2.7 million in the same quarter of 2025. The year-over-year increase of USD 0.5 million gives the company a measurable operating improvement, although the quarterly loss indicates that revenue growth has not yet translated into profitability.

The company recorded a second-quarter 2026 net loss of USD 0.18 per share. That figure remains the central earnings constraint for the stock because the USD 2.84 Nasdaq price on September 22, 2026 reflects a business that is still valued on future operating progress rather than current earnings.

Small-cap valuation stays sensitive

At USD 318.6 million in market capitalization as of September 22, 2026, Compose Cure remains a small-cap issuer. The comparison between USD 3.2 million of quarterly revenue and the current equity value highlights the valuation sensitivity: execution, cash use and the pace of commercial growth can have a material effect on the investment case.

The stock price and the latest operating figures therefore point in different directions. Revenue increased by USD 0.5 million year over year in the second quarter of 2026, but the company still reported a loss of USD 0.18 per share for that period.

Nasdaq price remains the reference

Compose Cure stock stood at USD 2.84 on Nasdaq as of September 22, 2026. The dated market value and the second-quarter 2026 revenue and EPS figures provide the clearest current reference points for assessing the company.